Premium
Interleukin‐12 Alters Helper T‐Cell Subsets and Antibody Profiles Induced by the Mucosal Adjuvant Cholera Toxin
Author(s) -
MARINARO MARIAROSARIA,
BOYAKA PROSPER N.,
JACKSON RAYMOND J.,
FINKELMAN FRED D.,
KIYONO HIROSHI,
McGHEE JERRY R.
Publication year - 1996
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.1996.tb52693.x
Subject(s) - cholera toxin , adjuvant , immune system , immunology , antibody , oral administration , medicine , antigen , toxin , biology , microbiology and biotechnology , pharmacology
We have shown that systemic administration of rmIL-12 could trigger Th1-type responses to a protein antigen delivered orally with CT as mucosal adjuvant. The most striking finding was that IL-12 could retain its regulatory effects when orally administered and could redirect the immune response to the oral vaccine toward a Th1-type. However, regulation by orally administered IL-12 differed from parenteral treatment with IL-12 since only the latter treatment affected mucosal S-IgA responses. These findings have important implications for the development of mucosal vaccines that induce the desired immune response.